A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer
Supportive Care in Cancer · 2026-10 · 34 (10)
DOI: 10.1007/s00520-026-11238-0 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Supportive Care in Cancer, online erschienen am 23.09.2026. Verfasst von Priya Patel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Group of Ontario, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Vomiting, Nausea, Palonosetron, Antineoplastic Agents. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) remains a significant challenge in pediatric oncology, with limited data guiding optimal antiemetic regimens. This phase 2 study evaluated pharmacokinetics (PK), pharmacodynamics, efficacy, and safety of oral netupitant combined with oral palonosetron (NEPA) in pediatric patients receiving highly or moderately emetogenic chemotherapy. METHODS: In this multicenter, randomized, double-blind, dose-finding study, pediatric patients ( 24-120h), and overall (0-120h) phases. PK parameters were derived from plasma concentrations of netupitant, its metabolites, and palonosetron. Safety was monitored through adverse events and clinical assessments. RESULTS: Among 65 evaluable patients, CR rates were 85.3%, 70.6%, and 70.6% in the lower netupitant dose group, and 87.1%, 71.0%, and 67.7% in the higher dose group, for the acute, delayed, and overall phases, respectively. CR was mostly consistent across age groups and chemotherapy emetogenicity. A trend toward increased CR with higher netupitant exposure (AUC0-inf) was observed in the delayed phase. The safety profile was consistent with expectations for cytotoxic chemotherapy, and no new safety signals were observed. CONCLUSION: A single dose of 4 mg/kg oral netupitant with oral palonosetron was effective and well-tolerated for CINV prevention in pediatric patients, supporting further investigation of NEPA in this population. TRIAL REGISTRATION: NCT03204279 [2 July 2017 registration date].
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Oncology Group of Ontario, Toronto, ON, Canada.
- Department of Pharmacy, The Hospital for Sick Children, Toronto, ON, Canada.
- Regional Children's Clinical Hospital #1, Ekaterinburg, Russia.
- Children's Territorial Clinical Hospital, Krasnodar, Russia.
- Dnipropetrovsk Regional Children's Clinical Hospital, Dnipro, Ukraine.
- Helsinn Healthcare SA, Lugano, Switzerland.
Zitieren
APA
Patel, P., Arakaev, O., Melnikov, M., Dementieva, N., Bernareggi, A., Chen, T., Spinelli, T., & Chaleff, S. (2026). A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer. Supportive Care in Cancer, 34(10). https://doi.org/10.1007/s00520-026-11238-0
Vancouver
Patel P, Arakaev O, Melnikov M, Dementieva N, Bernareggi A, Chen T, et al. A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer. Supportive Care in Cancer. 2026;34(10). doi:10.1007/s00520-026-11238-0
BibTeX
@article{Patel2026,
author = {Patel, Priya and Arakaev, Oleg and Melnikov, Mikhail and Dementieva, Nataliia and Bernareggi, Alberto and Chen, Tingchao and Spinelli, Tulla and Chaleff, Stanley},
title = {A phase 2 pharmacokinetic and pharmacodynamic dose-finding study of oral NEPA for chemotherapy-induced nausea and vomiting in pediatric patients with cancer},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {10},
doi = {10.1007/s00520-026-11238-0}
}
EUVIMED